Chronic administration of octreotide increases vascular responsiveness in rats with portal hypertension

Clinical Science

Volumn 91, Issue 5, 1996, Pages 601-606

  Huang, Yi Tsau ^a,c   Tsai, Ju Fen ^a,b   Liu, Tsun Bin ^a,c   Hong, Chuang Ye ^a   Yang, May C M ^a,c   Lin, Han Chieh ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Department of Medical Research ^*  (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Contractile response; Mesenteric artery; Octreotide; Phenylephrine; Portal hypertension; Vasopressin

Indexed keywords

GLUCAGON; HYPOTHALAMUS RELEASE INHIBITING FACTOR; OCTREOTIDE; PHENYLEPHRINE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; GLUCAGON BLOOD LEVEL; MESENTERIC ARTERY; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN LIGATION;

EID: 0029912664     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0910601     Document Type: Article

References (40)

1. Genecin P, Grosimann RJ. The biology of portai hypertension. In: Arias IM, Boyer JL, Fausto N. Jakoby WB, Schachter DA, Shafritt DA, eds. The liver: biology and pathobiology. 3rd edn. New York: Raven Press, 1994: 1327-41.
2. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6:287-98.
3. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103: 235-9.
4. Karatapanis S, McCormick PA, Kakad S, et al. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology 1994; 20: 1516-21.
5. 1-adrenoceptors of portal hypertensive rats. Br J Pharmacd 1994; 111:439-44.
6. Kiel JW, Pitts V. Benoit JN, Granger DN. Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats. Am J Physiol 1985; 248: G192-5.
7. Mesh CL, Joh T, Korthuis RJ, Granger DN, Benoit JN. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology 1991 ; 100:916-21.
8. Joh T, Granger DN, Benoit JN. Endogenous vasoconstrictor tone in intestine of normal and portal hypertensive rats. Am J Physiol 1993; 264: H171-7.
9. Murray BM, Palier MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats: Evidence for a post-receptor in angiotensin action. Ore Res 1985; 57: 424-31.
10. Sitzmann JV, Li S- S, Wu Y-P, Groszmann RJ, Buckley GB. Decreased mesenteric vascular response to angiotensin II in portal hypertension. J Surg Res 1990; 48: 341-4.
11. Sieber CC, Groszmann, RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992; 262: G996-.
12. Weigert AL, Martin P-Y, Niederberger M, et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology I99S; 22: 1856-62.
13. Bauer W, Briner U, Doepfner W, et al. SMS 201 -995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sei 1982:31:1133-40.
14. Battershill PE, Gissold SP. Octreotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38:658-702.
15. Hwang S-J, Lin H-C, Chang C-F, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. JHepatol1992;16:320-5.
16. Silvain C, Carpentier S, Sautereau D, et al. Terlipressin plus transdermal nitroglycerin versus octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1994; 18:61-5.
17. McCormick PA, Dick R, Siringo S, et al. Octreotide reduces azygous blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1992; 2:489-92.
18. tin H-C, Tsai Y-T, Lee F-Y, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992; 103:229-34.
19. jenkins SA, Baxter JN, Corbett WA. Shields R. The effects of a somatostatin analogue SMS 201-995 on hepatic and haemodynamics in the cirrhotic rat Br J Surg 1985; 72:864-7.
20. Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988; 94:703-708.
21. Hori N, Okanoue T, Sawa Y, Mori T, Kashima K. Effect of a somatostatin analogue (SMS 201-995) on hemodynamics and glucagon secretion in cirrhotic rats. Gastroenteroljpn 1993; 28: 276-83.
22. + retention in portal hypertensive rats. Gastroenterology 1993; 104:575-9.
23. Lin H-C, Yang MC-M, Hou M-C, et al. Effects of long-term administration of octreotide in portal vein Stenosed rats. Hepatology 1996; 23:537-43.
24. Sieber CC, Lee FY, Groszmann Rj. Chronic octreotide treatment prevents the in vitro hyporeactivity in portal hypertensive rats [Abstract]. Hepatology 1994; 19: 1241.
25. Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981 ; 240: G371 -5.
26. Burroughs AK. Octreotide in varkeal bleeding. Gut 1994; Suppl. 3: S23-7.
27. D'Amico G. Pagliaro L Bosch J. The treatment of portal hypertension: A meta-analytic review. Hepatology 1995; 22:332-54.
28. Imperiale TF, Teran JC, McCullouch AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995; 109:1289-94.
29. Lin H-C, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991; 13:213-19.
30. Lin H-C, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology 1991; 14:325-30.
31. ω-Nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105: 1464-70.
32. Pizcueta MP, Garcia-Pagan JC, Fernandez M, Casamitjana R, Bosch J, Rodes J. Glucagon hinders the effects of somatostatin on portal hypertension: A study in rats with partial portal vein ligation. Gastroenterology 1991; 101: 1710-15.
33. Kravetz D, Bosch J, Arderiu MT, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-8.
34. Benoit JN, Barrowman JA, Harper SL, Kvietys PG, Granger DN. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984; 247: G486-93.
35. Pizcueta MP, Casamitjana R, Bosch J. Rodes J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hypergtucagonism. Am J Physiol 1990; 258: G191-5.
36. Benoit JN, Zimmerman B, Premen AJ, Go VLW, Granger DN. Role of glucagon in the splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986; 25l:G674-7.
37. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992; 262: G274-7.
38. Michielson PP, Boeckxstaens GE, Sys SU, Herman AG, Pelckmans PA Role of nitric oxide in hyporeactivity to noradrenaline of isolated aortic rings in portal hypertensive rats. Eur J Pharmacd 1995; 273: 167-74.
39. Heinemann A, Stauber RE. The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats. Eur J Pharmacol 1995:278:87-90.
40. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 1343-50.